Welcome to our dedicated page for Abeona Therapeut news (Ticker: ABEO), a resource for investors and traders seeking the latest updates and insights on Abeona Therapeut stock.
Abeona Therapeutics Inc. develops and commercializes cell and gene therapies for serious diseases. Its updates center on ZEVASKYN (prademagene zamikeracel), an autologous cell-based gene therapy for wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa, including qualified treatment center activations, commercial launch activity, manufacturing and patient-treatment progress.
Company news also covers financial results, corporate progress, employee inducement equity awards under Nasdaq rules, board and committee changes, and development work involving AAV-based gene therapies and next-generation AAV capsids for ophthalmic and other serious diseases.
Abeona Therapeutics (Nasdaq: ABEO) reported Q1 2026 net product revenue of $8.7 million, up from $2.4 million in Q4 2025, driven by ZEVASKYN.
Three patients were treated in Q1, the QTC network expanded to six sites, coverage policies now span 95% of commercially insured U.S. lives, and cash totaled $168.3 million.
Abeona Therapeutics (Nasdaq: ABEO) has activated Children’s Hospital of Philadelphia (CHOP) as the sixth Qualified Treatment Center (QTC) for administering ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets to patients with recessive dystrophic epidermolysis bullosa (RDEB).
The designation expands access on the U.S. East Coast and is supported by Abeona Assist, a patient support program offering insurance, financial, travel, and logistical assistance.
Abeona Therapeutics (Nasdaq: ABEO) will report first-quarter 2026 financial results and host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET. The call is available by phone and via a live webcast, with an archived replay accessible on the company investor site for 30 days.
Dial-in numbers and an entry code are provided for live participation; a listen-only webcast and replay link are on the Abeona investor events page.
Abeona Therapeutics (Nasdaq: ABEO) announced restricted stock inducement awards for eight newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4). On April 30, 2026, the Compensation Committee granted awards covering up to 112,621 restricted shares. One-third of each award vests on each anniversary, fully vesting after three years subject to continued employment.
Abeona Therapeutics (Nasdaq: ABEO) appointed Keith A. Goldan to its Board of Directors, effective April 1, 2026. He will serve as Chairman of the Audit Committee and brings over two decades of financial leadership in biotech and specialty pharma.
Goldan’s background includes CFO roles at Syndax, Optinose and Fibrocell, experience leading product approvals and commercial launches, and a track record in capital markets, M&A and corporate development as Abeona advances its first U.S. commercial launch.
Abeona Therapeutics (Nasdaq: ABEO) granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4).
On March 31, 2026 the Compensation Committee approved restricted stock awards for four new non‑executive employees, covering up to 8,400 restricted shares. One‑third vests each year, with full vesting on the third anniversary, subject to continued employment.
Abeona Therapeutics (Nasdaq: ABEO) activated NewYork-Presbyterian/Columbia University Irving Medical Center as a new Qualified Treatment Center for ZEVASKYN (prademagene zamikeracel) on April 2, 2026. This marks the company's fifth QTC and expands patient access across the New York metropolitan area and the Northeast.
The announcement highlights collaboration with Columbia dermatology leadership and notes Abeona Assist offers insurance, financial, travel, and logistical support for eligible patients seeking ZEVASKYN.
Abeona Therapeutics (Nasdaq: ABEO) reported full‑year 2025 results and operational updates on March 17, 2026. Key 2025 items include $5.8M total revenue, $191.4M cash and short‑term investments at year‑end, and a $152.4M net gain from the sale of a Rare Pediatric Disease PRV. ZEVASKYN commercial launch began in Q4 2025 with the first commercial patient treated in December; treatments and biopsies resumed after a manufacturing shutdown and continued in early 2026.
The company noted rising SG&A from commercialization, a $1.5M cost of sales tied to initial production and a transition of certain costs from R&D to inventory post FDA approval.
Abeona Therapeutics (Nasdaq: ABEO) reported building momentum in the commercial launch of FDA-approved ZEVASKYN (prademagene zamikeracel) for RDEB.
After optimizing a release assay in 2025, launch activities began Q4 2025; first patient treated in December before a scheduled facility shutdown. Manufacturing resumed late January 2026 with multiple biopsies collected, one patient treated, ongoing runs, and more biopsies scheduled this quarter. Major commercial payers covering ~80% of commercial lives and all Medicaid programs have published policies. CMS established permanent HCPCS J-code J3389, effective January 1, 2026, to support billing and reimbursement.
Abeona Therapeutics (Nasdaq: ABEO) announced a conference call for its Q4 and full year 2025 results on Tuesday, March 17, 2026 at 8:30 a.m. ET, available by phone and webcast.
Management will also participate in a fireside chat at the 2026 Leerink Global Healthcare Conference on March 10, 2026 at 8:40 a.m. ET; both webcasts will be archived for 30 days on the company’s Investors & Media events page.